BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 23772082)

  • 1. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada.
    Bourré-Tessier J; Clarke AE; Mikolaitis-Preuss RA; Kosinski M; Bernatsky S; Block JA; Jolly M
    J Rheumatol; 2013 Aug; 40(8):1327-33. PubMed ID: 23772082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The French-Canadian validation of a disease-specific, patient-reported outcome measure for lupus.
    Bourré-Tessier J; Clarke AE; Kosinski M; Mikolaitis-Preuss RA; Bernatsky S; Block JA; Jolly M
    Lupus; 2014 Dec; 23(14):1452-9. PubMed ID: 25081500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines.
    Navarra SV; Tanangunan RM; Mikolaitis-Preuss RA; Kosinski M; Block JA; Jolly M
    Lupus; 2013 Mar; 22(3):262-7. PubMed ID: 23340995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turkish lupusPRO: cross-cultural validation study for lupus.
    Kaya A; Goker B; Cura ES; Tezcan ME; Tufan A; Mercan R; Bitik B; Haznedaroglu S; Ozturk MA; Mikolaitis-Preuss RA; Block JA; Jolly M
    Clin Rheumatol; 2014 Aug; 33(8):1079-84. PubMed ID: 23934384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spanish LupusPRO: cross-cultural validation study for lupus.
    Jolly M; Toloza S; Block J; Mikolaitis R; Kosinski M; Wallace D; Durran-Barragan S; Bertoli A; Blazevic I; Vilá L; Cooray D; Moldovan I; Katsaros E; Weisman M; Torralba KM; Alarcón G
    Lupus; 2013 Apr; 22(5):431-6. PubMed ID: 23554032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Arabic LupusPRO: A Cross-Cultural Validation of a Disease-Specific Patient-Reported Outcome Tool for Quality of Life in Lupus Patients.
    Elkaraly NE; Nasef SI; Omar AS; Fouad AM; Jolly M; Mohamed AE
    Lupus; 2020 Nov; 29(13):1727-1735. PubMed ID: 32878556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hindi LupusPRO: cross cultural validation of disease specific patient reported outcome measure of lupus.
    Pinto B; Jolly M; Dhooria A; Grover S; Raj JM; Devilliers H; Sharma A
    Lupus; 2019 Nov; 28(13):1534-1540. PubMed ID: 31635557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus.
    Mok CC; Kosinski M; Ho LY; Chan KL; Jolly M
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):297-304. PubMed ID: 25156199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the LupusPRO version 1.8: an update to a disease-specific patient-reported outcome tool for systemic lupus erythematosus.
    Azizoddin DR; Weinberg S; Gandhi N; Arora S; Block JA; Sequeira W; Jolly M
    Lupus; 2018 Apr; 27(5):728-737. PubMed ID: 29087259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-specific patient reported outcome tools for systemic lupus erythematosus.
    Jolly M; Pickard AS; Block JA; Kumar RB; Mikolaitis RA; Wilke CT; Rodby RA; Fogg L; Sequeira W; Utset TO; Cash TF; Moldovan I; Katsaros E; Nicassio P; Ishimori ML; Kosinsky M; Merrill JT; Weisman MH; Wallace DJ
    Semin Arthritis Rheum; 2012 Aug; 42(1):56-65. PubMed ID: 22480408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT.
    Conti F; Perricone C; Reboldi G; Gawlicki M; Bartosiewicz I; Pacucci VA; Massaro L; Miranda F; Truglia S; Alessandri C; Spinelli FR; Teh LS; Ceccarelli F; Valesini G
    Lupus; 2014 Jul; 23(8):743-51. PubMed ID: 24569393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Korean LupusPRO: Cross-Cultural validation study for systemic lupus erythematosus.
    Han JY; Cho SK; Nam E; Kim H; Lee SS; Jolly M; Sung YK
    Lupus; 2022 Oct; 31(12):1498-1507. PubMed ID: 36017605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus.
    Stoll T; Gordon C; Seifert B; Richardson K; Malik J; Bacon PA; Isenberg DA
    J Rheumatol; 1997 Aug; 24(8):1608-14. PubMed ID: 9263159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Japanese LupusPRO: A cross-cultural validation of an outcome measure for lupus.
    Inoue M; Shiozawa K; Yoshihara R; Yamane T; Shima Y; Hirano T; Jolly M; Makimoto K
    Lupus; 2017 Jul; 26(8):849-856. PubMed ID: 27927882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity and Reliability of Patient Reported Outcomes Measurement Information System Computerized Adaptive Tests in Systemic Lupus Erythematosus.
    Kasturi S; Szymonifka J; Burket JC; Berman JR; Kirou KA; Levine AB; Sammaritano LR; Mandl LA
    J Rheumatol; 2017 Jul; 44(7):1024-1031. PubMed ID: 28412708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices.
    Moore AD; Clarke AE; Danoff DS; Joseph L; Bélisle P; Neville C; Fortin PR
    J Rheumatol; 1999 Jun; 26(6):1285-90. PubMed ID: 10381044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus.
    Harrison MJ; Ahmad Y; Haque S; Dale N; Teh LS; Snowden N; Ho P; Gorodkin R; Bruce IN
    J Rheumatol; 2012 Apr; 39(4):735-42. PubMed ID: 22298908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-group confirmatory factor analyses of the LupusPRO between southern California and Filipino samples of patients with systemic lupus erythematosus.
    Azizoddin DR; Olmstead R; Cost C; Jolly M; Ayeroff J; Racaza G; Sumner LA; Ormseth S; Weisman M; Nicassio PM
    Lupus; 2017 Aug; 26(9):967-974. PubMed ID: 28059025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of the Lupus Impact Tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus.
    Jolly M; Garris CP; Mikolaitis RA; Jhingran PM; Dennis G; Wallace DJ; Clarke A; Dooley MA; Parke A; Strand V; Alárcon GS; Kosinski M
    Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1542-50. PubMed ID: 24757021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.